Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918749 · ClinicalTrials.gov registry record · Phase 2
Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
A Phase 2 study of Postmenopausal Osteoporosis, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
- 6
- Study locations
NCT00918749 is a Phase 2 study of Postmenopausal Osteoporosis that has completed, run by Warner Chilcott. The registered enrollment target is 205 participants, below the 569-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target (64% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00918749, a Phase 2 study of Postmenopausal Osteoporosis, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
- 6
- Study locations
Study Summary
Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatment regimens for 3 months.
Conditions Studied
Interventions
- DRUG 150 mg
- DRUG 75 mg
- DRUG 100 mg
Study Locations (6)
Florida
- Research Site - Daytona Beach
- Research Site - Fort Myers
Texas
- Research Site - Austin
- Research Site - Dallas
Hawaii
- Research Site - Honolulu
Indiana
- Research Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918749
The ClinicalTrials.gov registry entry for NCT00918749 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target (64% lower). The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 3 interventions - of which 150 mg is the first listed.
NCT00918749 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, Texas, Hawaii.
Frequently Asked Questions
What is clinical trial NCT00918749 about?
NCT00918749 is a clinical study titled "Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women". Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatmen...
What is the current status of trial NCT00918749?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2009-05. Estimated completion is 2009-10.
What conditions does trial NCT00918749 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT00918749?
The interventions under investigation include: 150 mg (DRUG), 75 mg (DRUG), 100 mg (DRUG).
Who is sponsoring clinical trial NCT00918749?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00918749 being conducted?
This trial has 6 study locations across Florida, Hawaii, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
ACTIVE NOT RECRUITING · Phase 2
-
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
COMPLETED · Phase 2
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
-
Anabolic Therapy in Postmenopausal Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
-
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.